Time to re-appraise the role of alpha-1 adrenoceptor antagonists in the management of hypertension?

Journal of Hypertension

Volumn 28, Issue 9, 2010, Pages 1796-1803

  Chapman, Neil ^a   Chen, Chung Yin ^b   Fujita, Toshiro ^c   Hobbs, Fd Richard ^d   Kim, Soo Joong ^e   Staessen, Jan A ^f,g   Tanomsup, Supachai ^h   Wang, Ji Guang ⁱ   Williams, Bryan ^j  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b Kuang Tai chung General Hospital   (Taiwan)

^c UNIVERSITY OF TOKYO   (Japan)

^d UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^e Kyung Hee University Hospital   (South Korea)

^f UNIVERSITY OF LEUVEN   (Belgium)

^g MAASTRICHT UNIVERSITY   (Netherlands)

^h MAHIDOL UNIVERSITY   (Thailand)

ⁱ SHANGHAI SECOND MEDICAL UNIVERSITY   (China)

^j UNIVERSITY OF LEICESTER   (United Kingdom)

more..

Author keywords

alpha blockers; doxazosin; gastrointestinal therapeutic system; hypertension; metabolic effects

Indexed keywords

ALFUZOSIN; APOLIPOPROTEIN B; CHLORTALIDONE; DOXAZOSIN; ENALAPRIL; GLUCOSE; HIGH DENSITY LIPOPROTEIN; LIPID; LOW DENSITY LIPOPROTEIN; PLACEBO; PRAZOSIN; PROPRANOLOL; TERAZOSIN;

ADD ON THERAPY; ANTIHYPERTENSIVE THERAPY; ASTHENIA; BLOOD PRESSURE REGULATION; CHOLESTEROL BLOOD LEVEL; DIZZINESS; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HEADACHE; HEART FAILURE; HUMAN; HYPERTENSION; IMPOTENCE; LIPID METABOLISM; LIPOPROTEIN BLOOD LEVEL; PRIORITY JOURNAL; REVIEW; SINGLE DRUG DOSE; STATISTICAL SIGNIFICANCE; SYNCOPE;

EID: 77955851626     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/HJH.0b013e32833b912c     Document Type: Review

References (47)

1. Fukiyama K, Omae T, Iimura O, Yoshinaga K, Yagi S, Inagaki Y, et al. A double-blind comparative study of doxazosin and prazosin in the treatment of essential hypertension. Am Heart J 1991; 121:317-322.
2. Sega R, Marazzi ME, Bombelli M, Vulpis V, Antonacci A, Leto di Priolo S, et al. Comparison of the new alpha-1 blocker alfuzosin with propranolol as first-line therapy in hypertension. Pharmacol Res 1991; 24:41-52.
3. Itskovitz HD. Alpha 1-blockade for the treatment of hypertension: a megastudy of terazosin in 2214 clinical practice settings. Clin Ther 1994; 16:490-504.
4. Joglekar SJ, Nanivadekar AS. A randomized, controlled, multicenter study to compare prazosin GITS with enalapril in hypertensive patients with diabetes mellitus. J Assoc Physicians India 1998; (Suppl 1): 52-62.
5. Neaton JD, Grimm RH Jr, Prineas RJ, Stamler J, Grandits GA, Elmer PJ, et al. Treatment of Mild Hypertension Study. Final results. J Am Med Assoc 1993; 270:713-724.
6. Os I, Stokke HP. Effects of doxazosin in the gastrointestinal therapeutic system formulation versus doxazosin standard and placebo in mild-to-moderate hypertension. Doxazosin Investigators' Study Group. J Cardiovasc Pharmacol 1999; 33:791-797.
7. Calvo C, Gil-Extremera B, Gomez-Fernández P, Masramon X, Pueyo C, Armada B. Doxazosin GITS versus standard doxazosin in mild to moderate hypertension. Int J Cardiol 2005; 101:97-104.
8. Os I. Comparison of doxazosin GITS and standard doxazosin in the treatment of high blood pressure. Int J Clin Pharmacol Ther 2006; 44:99-106.
9. Black HR, Sollins JS, Garofalo JL. The addition of doxazosin to the therapeutic regimen of hypertensive patients inadequately controlled with other antihypertensive medications: a randomized, placebo-controlled study. Am J Hypertens 2000; 13:468-474.
10. Lehtonen A. Doxazosin effects on insulin and glucose in hypertensive patients. The Finnish Multicenter Study Group. Am Heart J 1991; 121:1307-1311.
11. Huupponen R, Lehtonen A, Vahatalo M. Effect of doxazosin on insulin sensitivity in hypertensive noninsulin dependent diabetic patients. Eur J Clin Pharmacol 1992; 43:365-368.
12. Maheux P, Facchini F, Jeppesen J, Greenfield MS, Clinkingbeard C, Chen YD, Reaven GM. Changes in glucose, insulin, lipid, lipoprotein, and apoprotein concentrations and insulin action in doxazosin-treated patients with hypertension. Comparison between nondiabetic individuals and patients with noninsulin-dependent diabetes mellitus. Am J Hypertens 1994; 7:416-424.
13. Levy D, Walmsley P, Levenstein M. Principal results of the Hypertension and Lipid Trial (HALT): a multicenter study of doxazosin in patients with hypertension. Am Heart J 1996; 131:966-973.
14. Grimm RH Jr, Flack JM, Grandits GA, Elmer PJ, Neaton JD, Cutler JA, et al. Long-term effects on plasma lipids of diet and drugs to treat hypertension. Treatment of Mild Hypertension Study (TOMHS) Research Group. J Am Med Assoc 1996; 275:1549-1556.
15. Daae LN, Westlie L. A 5-year comparison of doxazosin and atenolol in patients with mild-to-moderate hypertension: effects on blood pressure, serum lipids, and coronary heart disease risk. Blood Press 1998; 7:39-45.
16. Hirano T, Yoshino G, Kashiwazaki K, Adachi M. Doxazosin reduces prevalence of small dense low density lipoprotein and remnant-like particle cholesterol levels in nondiabetic and diabetic hypertensive patients. Am J Hypertens 2001; 14:908-913.
17. Kinoshita M, Shimazu N, Fujita M, Fujimaki Y, Kojima K, Mikuni Y, et al. Doxazosin, an alpha1-adrenergic antihypertensive agent, decreases serum oxidized LDL. Am J Hypertens 2001; 14:267-270.
18. Hobbs FR, Khan T, Collins B. Doxazosin versus bendrofluazide: a comparison of the metabolic effects in British South Asians with hypertension. Br J Gen Pract 2005; 55:437-443.
19. Derosa G, Cicero AF, D'Angelo A, Ragonesi PD, Ciccarelli L, Fogari E, et al. Synergistic effect of doxazosin and acarbose in improving metabolic control in patients with impaired glucose tolerance. Clin Drug Investig 2006; 26:529-539.
20. Lepor H. Role of alpha adrenergic blockers in the treatment of benign prostatic hypertrophy. Prostate Suppl 1990; 3:75-84.
21. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs. chlorthalidone: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). J Am Med Assoc 2000; 283:1967-1975.
22. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42:1206-1252.
23. O'Callaghan CJ, Williams B. The regulation of human vascular smooth muscle extracellular matrix protein production by alpha-and beta-adrenoceptor stimulation. J Hypertens 2002; 20:287-294.
24. Iwamoto N, Abe-Dohmae S, Ayaori M, Tanaka N, Kusuhara M, Ohsuzu F, et al. ATP-binding cassette transporter A1 gene transcription is downregulated by activator protein 2alpha. Doxazosin inhibits activator protein 2alpha and increases high-density lipoprotein biogenesis independent of alpha1-adrenoceptor blockade. Circ Res 2007; 101: 156-165.
25. Black HR. Doxazosin as combination therapy for patients with stage 1 and stage 2 hypertension. J Cardiovasc Pharmacol 2003; 41:866-869.
26. Black HR, Keck M, Meredith P, Bullen K, Quinn S, Koren A. Controlled-release doxazosin as combination therapy in hypertension: The GATES study. J Clin Hypertens (Greenwich) 2006; 8:159-166.
27. Chapman N, Chang CL, Dahlof B, Sever PS, Wedel H, Poulter NR, ASCOT Investigators. Effect of doxazosin gastrointestinal therapeutic system as third-line antihypertensive therapy on blood pressure and lipids in the Anglo-Scandinavian Cardiac Outcomes Trial. Circulation 2008; 118:42-48.
28. Kanagy NL. Alpha(2)-adrenergic receptor signalling in hypertension. Clin Sci (Lond) 2005; 109:431-437.
29. Sonders RC. Pharmacokinetics of terazosin. Am J Med 1986; 80 (Suppl 5B):20-22.
30. DiPiro JT. Controlling drug effects through improved oral formulations. The pharmacokinetics of the prazosin gastrointestinal therapeutic system. Am J Med 1989; 87:31S-35S.
31. Fourtillan JB, Brisson AM, Couet W. Pharmacokinetics of prazosin administered as gastrointestinal-therapeutics-systems to 24 healthy volunteers. Therapie 1993; 48:115-118.
32. Chung M, Vashi V, Puente J, Sweeney M, Meredith P. Clinical pharmacokinetics of doxazosin in a controlled-release gastrointestinal therapeutic system (GITS) formulation. Br J Clin Pharmacol 1999; 48:678-687.
33. Hermida RC, Calvo C, Ayala DE, Dominguez MJ, Covelo M, Fernandez JR, et al. Administration-time-dependent effects of doxazosin GITS on ambulatory blood pressure of hypertensive subjects. Chronobiol Int 2004; 21:277-296.
34. Kario K, Schwartz JE, Pickering TG. Changes of nocturnal blood pressure dipping status in hypertensives by nighttime dosing of alpha-adrenergic blocker, doxazosin: results from the HALT study. Hypertension 2000; 35:787-794.
35. Grimm RH Jr, Grandits GA, Prineas RJ, McDonald RH, Lewis CE, Flack JM, et al. Long-term effects on sexual function of five antihypertensive drugs and nutritional hygienic treatment in hypertensive men and women. Treatment of Mild Hypertension Study (TOMHS). Hypertension 1997; 29:8-14.
36. Messerli FH. Implications of discontinuation of doxazosin arm of ALLHAT. Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Lancet 2000; 355:863-864.
37. Poulter N, Williams B. Doxazosin for the management of hypertension: implications of the findings of the ALLHAT trial. Am J Hypertens 2001; 14:1170-1172.
38. Pillar LB, Davis BR, Cutler JA, Cushman WC, Wright JT Jr, Williamson JD, et al. Validation of heart failure events in the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) participants assigned to doxazosin and chlorthalidone. Curr Control Trials Cardiovasc Med 2002; 3:10.
39. de Alvaro F, Hernández-Presa MA, ASOCIA Study. Effect of doxazosin gastrointestinal therapeutic system on patients with uncontrolled hypertension: The ASOCIA Study. J Cardiovasc Pharmacol 2006; 47:271-276.
40. Sever PS, Dahlof B, Poulter NR, Wedel H, Beevers G, Caulfield M, et al. Rationale, design, methods and baseline demography of participants of the Anglo-Scandinavian Cardiac Outcomes Trial. J Hypertens 2001; 19:1139-1147.
41. Gupta AK, Dahlof B, Dobson J, Sever PS, Wedel H, Poulter NR, Anglo-Scandinavian Cardiac Outcomes Trial Investigators. Determinants of new-onset diabetes among 19,257 hypertensive patients randomized in the Anglo-Scandinavian Cardiac Outcomes Trial-blood pressure lowering arm and the relative influence of antihypertensive medication. Diabetes Care 2008; 31:982-988.
42. British Cardiac Society, British Hypertension Society, Diabetes UK, HEART UK, Primary Care Cardiovascular Society, The Stroke Association. JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice. Heart 2005; 91(Suppl 5):v1-v52.
43. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25:1105-1187.
44. Williams B, Poulter NR, Brown MJ, Davis M, McInnes GT, Potter JF, et al. Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004-BHS IV. J Hum Hypertens 2004; 18:139-185.
45. National Institute for Health and Clinical Excellence (NICE). Hypertension: managementofhypertensioninadultsinprimarycare. NICEweb site.Acces-sed on February 11, 2008 from http://www.nice.org.uk/guidance/CG34.
46. Lindholm LH, Carlberg B, Samuelsson O.Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet 2005; 366:1545-1553.
47. MasonJM, DickinsonHO,NicolsonDJ,CampbellF,FordGA,WilliamsB.The diabetogenic potential of thiazide-type diuretic and beta-blocker combinations in patients with hypertension. J Hypertens 2005; 23:1777-1781.